CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 136 enrolled
Drug / intervention
3 g Polynucleotide vaginal suppositories +1 moredrug
Likely dose
3 g Polynucleotide vaginal suppositoriesfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05464654
NCT05464654N/ACompleted

VABIP Study (Vaginal Biorevitalization With Polydeoxyribonucleotides) for the Improvement of the Genitourinary Syndrome of Menopause

Hospital Regional 1o de Octubre·interventional·Posted Jul 19, 2022·Updated Apr 11, 2023

In Brief

A clinical study evaluating 3 g Polynucleotide vaginal suppositories and Conjugated estrogens cream 1g Tube for Genitourinary Syndrome of Menopause and 3 related conditions. Completed, enrolled 136 participants across 1 site.

Detailed Summary

The aim of the study was to compare the efficacy of vaginal biorevitalization to improve the genitourinary syndrome of menopause (GSM) between the gold-standard treatment with local estrogen-based hormone therapy versus local salmon polydeoxyribonucleotide (PDRN) therapy.

Study Details

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJul 19, 2022
Enrollment StartJun 23, 2021
Primary CompletionNov 23, 2021
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.0 years ago

Interventions

3 g Polynucleotide vaginal suppositoriesdrug

3 g polynucleotide vaginal suppositories were administered nightly for 6 days.

Conjugated estrogens cream 1g Tubedrug

Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.